Apixaban 2.5 MG

DRUG13 trials

Conditions

Aortic Valve DiseaseAortic Valve FailureAortic Valve StenosisBleedingCOVID-19CirrhosisCovid19Deep Vein Thrombosis

Phase 2

A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery

CompletedNCT03251482

Janssen Research & Development, LLCVTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery

Start: 2017-11-13End: 2018-11-05Updated: 2019-11-25

Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDs

TerminatedNCT04106700

Instituto de Investigacion Sanitaria La FeVenous Thromboembolism

Start: 2019-04-12End: 2020-10-05Updated: 2021-02-15

Phase 3

PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban

TerminatedNCT04142658

Artivion Inc.Aortic Valve Disease, Aortic Valve Failure, Aortic Valve Stenosis

Start: 2020-05-01End: 2022-12-12Updated: 2024-03-20

COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80

TerminatedNCT04498273

Frank C SciurbaCOVID-19

Start: 2020-09-07End: 2021-08-05Updated: 2022-02-17

COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis

CompletedNCT04650087

Thomas L. OrtelCovid19

Start: 2021-02-15End: 2022-09-23Updated: 2025-02-25

Phase 4

Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism

TerminatedNCT03196349

Duke UniversityVenous Thromboembolism

Start: 2018-08-01End: 2019-05-01Updated: 2019-12-13

Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism

CompletedNCT04168203

Brigham and Women's HospitalDeep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism

Start: 2021-03-01End: 2025-04-08Updated: 2025-11-14

Apixaban for Prevention of Post-angioplasty Thrombosis of Hemodialysis Vascular Access

NCT04489849

National Taiwan University Hospital Hsin-Chu BranchHemodialysis Access Failure

Start: 2020-03-14End: 2022-06-14Target: 150Updated: 2020-07-28

Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19

TerminatedNCT04746339

Brazilian Clinical Research InstituteCovid19, Thrombosis

Start: 2021-03-04End: 2022-05-30Updated: 2022-08-25

Avoiding Risks of Thrombosis and Bleeding in Surgery (ARTS) Trial

RecruitingNCT06523959

Clinical Urology and Epidemiology Working GroupBleeding, Venous Thromboembolism

Start: 2024-06-06End: 2028-12-31Target: 5436Updated: 2025-05-28

Unknown Phase

Apixaban Prevents Portal Vein Thrombosis After Laparoscopic Splenectomy and Azygoportal Disconnection

CompletedNCT05304455

Northern Jiangsu People's HospitalCirrhosis, Hypertension, Portal, Splenectomy +1

Start: 2022-04-01End: 2023-05-31Updated: 2023-12-21

Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS

RecruitingNCT07461545

Northern Jiangsu People's HospitalCirrhosis, Hypertension, Portal, Portal Vein Thrombosis +1

Start: 2026-04-01End: 2027-09-30Target: 20Updated: 2026-03-31

Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD

RecruitingNCT07461532

Northern Jiangsu People's HospitalCirrhosis, Hypertension, Portal, Portal Vein Thrombosis +1

Start: 2026-04-01End: 2027-09-30Target: 20Updated: 2026-03-31

New England Journal of Medicine2025-08-3016 citations

Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization

UNC Libraries2025-03-18

A randomized controlled trial evaluated the efficacy and safety of apixaban for prevention of recurrent thrombosis after thrombectomy of hemodialysis vascular access.

2024-11-161 citations

Clinically stable covid-19 patients presenting to acute unscheduled episodic care venues have increased risk of hospitalization: secondary analysis of a randomized control trial

BMC Infectious Diseases2023-05-151 citations

Apixaban or Warfarin in Patients with an On-X Mechanical Aortic Valve

NEJM Evidence2023-05-06107 citations

Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization.

2023-03-2121 citations

Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial.

2022-06-3043 citations

Chronic Oral Anticoagulation Therapy and Prognosis of Patients Admitted to Hospital for COVID‐19: Insights from the HOPE COVID‐19 Registry

International Journal of Clinical Practice2022-01-015 citations

Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial.

2021-12-15177 citations

Benefit–Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER

Journal of the American Heart Association2021-11-1012 citations

Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19

JAMA2021-10-17261 citations